These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 21176009)
1. Clinical perspective: biomarkers in pulmonary arterial hypertension. Heresi GA Int J Clin Pract Suppl; 2011 Jan; (169):5-7. PubMed ID: 21176009 [TBL] [Abstract][Full Text] [Related]
2. Pulmonary arterial hypertension: evaluation of the newly diagnosed patient. Torbicki A; Kurzyna M Semin Respir Crit Care Med; 2005 Aug; 26(4):372-8. PubMed ID: 16121313 [TBL] [Abstract][Full Text] [Related]
3. Biomarkers in pulmonary arterial hypertension. Rafeq S; Shah AM; Preston IR Int J Clin Pract Suppl; 2009 Sep; (162):36-41. PubMed ID: 19624798 [TBL] [Abstract][Full Text] [Related]
4. [Seven years of experience in patients with pulmonary arterial hypertension in Ege University Hospital: diagnostic approach of a single center]. Kayikçioğlu M; Kültürsay H Anadolu Kardiyol Derg; 2008 Aug; 8(4):279-85. PubMed ID: 18676304 [TBL] [Abstract][Full Text] [Related]
5. The potential of biomarkers in pulmonary arterial hypertension. Cracowski JL; Leuchte HH Am J Cardiol; 2012 Sep; 110(6 Suppl):32S-38S. PubMed ID: 22921030 [TBL] [Abstract][Full Text] [Related]
6. Exercise as an end-point in pulmonary hypertension trials. McCullagh B; Girgis RE Int J Clin Pract Suppl; 2010 Jan; (165):4-6. PubMed ID: 19958394 [TBL] [Abstract][Full Text] [Related]
7. Medical treatment of pulmonary arterial hypertension. Adamali H; Gaine SP; Rubin LJ Semin Respir Crit Care Med; 2009 Aug; 30(4):484-92. PubMed ID: 19634087 [TBL] [Abstract][Full Text] [Related]
14. [Clinical end-points and surrogate markers of pulmonary arterial hypertension in the light of evidence-based treatment]. Can MM; Kaymaz C Anadolu Kardiyol Derg; 2010 Aug; 10 Suppl 1():36-42. PubMed ID: 20819765 [TBL] [Abstract][Full Text] [Related]
15. [Investigation of pulmonary hypertension]. Natali D; Simonneau G; Humbert M; Montani D Rev Pneumol Clin; 2008 Jun; 64(3):151-61. PubMed ID: 18656791 [TBL] [Abstract][Full Text] [Related]
16. Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival. Sajan I; Manlhiot C; Reyes J; McCrindle BW; Humpl T; Friedberg MK Am Heart J; 2011 Sep; 162(3):562-8. PubMed ID: 21884877 [TBL] [Abstract][Full Text] [Related]
17. Surrogate end points for pulmonary arterial hypertension. Kawut SM; Palevsky HI Am Heart J; 2004 Oct; 148(4):559-65. PubMed ID: 15459583 [TBL] [Abstract][Full Text] [Related]
18. Use of outcome measures in pulmonary hypertension clinical trials. Parikh KS; Rajagopal S; Arges K; Ahmad T; Sivak J; Kaul P; Shah SH; Tapson V; Velazquez EJ; Douglas PS; Samad Z Am Heart J; 2015 Sep; 170(3):419-29.e3. PubMed ID: 26385024 [TBL] [Abstract][Full Text] [Related]
19. Perspective on the optimal endpoints for pulmonary arterial hypertension trials. Rubin L; Simonneau G Curr Opin Pulm Med; 2010 May; 16 Suppl 1():S43-6. PubMed ID: 20375664 [TBL] [Abstract][Full Text] [Related]